Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acta Gastroenterol Belg ; 82(2): 285-290, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31314190

RESUMO

BACKGROUND AND AIM: Intestinal barrier dysfunction has been implicated in the development of infectious complications of acute pancreatitis. Nucleotide-Binding Oligomerization DomainContaining Protein 2 (NOD2) plays an important role in the proper functioning of intestinal defense mechanisms. Here, we investigated the frequency of NOD2 variants in patients with mild and severe acute pancreatitis. MATERIALS AND METHODS: Groups 1, 2 and 3 comprised healthy participants and patients with mild and severe pancreatitis, respectively. Four NOD2 variants and serum interleukin-6 (IL-6), Tumor Necrosis Factor-a (TNF-a) and lipopolysaccharide-binding protein (LBP) levels were analyzed. RESULTS: Three patients (3/32, 9.4%) in the severe pancreatitis group were positive for the p.R702W variant. This variant was negative in other groups. One, three and three patients in the healthy (1/27, 3.7%), mild (3/36, 8.3%) and severe pancreatitis (3/32, 9.4%) groups tested positive for the 1007fs variant, respectively. No significant differences in the frequencies of NOD2 variants were evident among the groups. Serum IL-6, TNF-a and LBP levels were markedly higher in the severe pancreatitis than the healthy and mild pancreatitis groups (all p<0.001). We observed no significant correlation between cytokine levels and NOD2 variants. CONCLUSION: Our results support an association between the presence of the p.R702W variant and severe pancreatitis.


Assuntos
Proteínas de Transporte/sangue , Interleucina-6/sangue , Glicoproteínas de Membrana/sangue , Proteína Adaptadora de Sinalização NOD2/metabolismo , Pancreatite/sangue , Fator de Necrose Tumoral alfa/sangue , Doença Aguda , Proteínas de Fase Aguda/metabolismo , Proteínas de Transporte/metabolismo , Estudos de Casos e Controles , Voluntários Saudáveis , Humanos , Interleucina-6/metabolismo , Intestinos , Glicoproteínas de Membrana/metabolismo , Nucleotídeos , Pancreatite/diagnóstico , Índice de Gravidade de Doença , Fator de Necrose Tumoral alfa/metabolismo
2.
Langenbecks Arch Surg ; 404(7): 875-883, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31327033

RESUMO

BACKGROUND: Studies reporting outcomes of endoscopic treatment methods in children who underwent liver transplantation (LT) is very limited. We present our outcomes, as a high-volume transplant center where endoscopic methods are preferred as the first choice in the treatment of biliary complications in children. METHODS: Patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) as the first treatment approach for biliary complications after LT between 2005 and 2017 were included. Clinical data included patient demographics, ERCP indications (stricture or leak), and treatment outcomes, including the need for percutaneous and surgical intervention. RESULTS: ERCP was performed in 49 patients who had a duct-to-duct anastomosis (38 living donor liver transplantation (LDLT), 11 deceased donor liver transplantation (DDLT)). The most common biliary complication was stricture. Our endoscopic success rate was 66.7% (18/27) and 75% (6/8) in LDLT and DDLT patients with stricture (p > 0.05), respectively. While our endoscopic success rate was 75% (3/4) in patients with leak alone after LDLT, it was 25% (1/4) in patients with leak and stricture in this group. The endoscopic success rate was 50% in two patients who had leak alone after DDLT. CONCLUSIONS: ERCP should be considered as a preferential treatment option for the management of biliary complications in pediatric liver transplant patients with duct-to-duct anastomosis, as in adults.


Assuntos
Anastomose Cirúrgica , Ductos Biliares/cirurgia , Colangiopancreatografia Retrógrada Endoscópica , Transplante de Fígado/métodos , Complicações Pós-Operatórias/cirurgia , Adolescente , Criança , Pré-Escolar , Feminino , Hospitais com Alto Volume de Atendimentos , Humanos , Masculino , Reoperação , Estudos Retrospectivos
3.
Acta Gastroenterol Belg ; 81(2): 283-287, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30024700

RESUMO

BACKGROUND AND AIM: Biliary complications are an important cause of mortality and morbidity after living donor liver transplantation (LDLT). We present our endoscopic treatment results after LDLT as a single center with high volume. METHODS: Patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) after LDLT between 2005 and 2015 were included. Clinical data included patient demographics, ERCP indications (stricture or leak), and treatment outcomes, including need for percutaneous and surgical interventions. RESULTS: ERCP was performed in 446 (39.2%) patients with duct-to-duct anastomosis of 1136 LDLT patients. The most common biliary complication was stricture ± stone (70.6%, 315/446). Stricture and leak occurred in 60 (13.4%) patients. Only biliary leak was found in 40 (8.9%) patients. Our endoscopic treatment success rate in patients with biliary stricture after LDLT was 65.1%. Overall endoscopic success rates in our patients were 55.0% in patients with both leak and stricture, and only leak. In all, our percutaneous transhepatic biliary interventions (PTBI) and ERCP success rate was 90.6% in patients with biliary complications after LDLT. CONCLUSIONS: Endoscopic treatments are highly effective for biliary complications after LDLT. Effective use of percutaneous interventions in collaboration with endoscopic treatments significantly reduces the need for surgical treatment.


Assuntos
Doenças Biliares/cirurgia , Colangiopancreatografia Retrógrada Endoscópica/métodos , Transplante de Fígado/métodos , Doadores Vivos , Complicações Pós-Operatórias/cirurgia , Anastomose Cirúrgica , Feminino , Fluoroscopia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Turquia
4.
J Neonatal Perinatal Med ; 8(2): 149-55, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26410440

RESUMO

BACKGROUND: Vancomycin a frequently used antimicrobial for the treatment of late-onset neonatal sepsis. It can be infused either intermittently or continuously, however, there is no consensus on the optimal dosing regimen. AIM: To evaluate microbiological outcomes, clinical response and adverse events of vancomycin when administered via continuos intravenous infusion. METHODS: The files of preterm infants (<34 weeks), who received either intermittent (group I, n = 41) or continuous (group II, n = 36) vancomycin infusion for the treatment of late-onset sepsis, were investigated retrospectively. Clinical and demographic features were recorded. RESULTS: Clinical improvement rates, Töllner scores and microbiological outcomes did not differ significantly between groups. At 48th hour of vancomycin infusion, 52.8% of infants achieved therapeutic concentrations of vancomycin in group II compared with 34.1% of patients in group I (p = 0.002). Thirty-nine percent of infants in group I had supratherapeutic concentrations of vancomycin at 48th hour compared with 5.6% in group II (p = 0.002). Dose adjustment rate in group I did not differ than group II (65.9% vs. 52.8% respectively, p = 0.3). However, when we subdivide group I into two according to dosing intervals, dose adjustment rates were more common in infants with a gestational age <29 weeks for whom intermittent infusion was performed in 18 hours intervals (92.9% vs 51.9% , p = 0.014). CONCLUSION: In preterm infants, continuous and intermittent infusions of vancomycin have similar clinical efficacies. Continuous infusion is well-tolerated and require less blood sampling compared to intermittent infusion especially in infants less than 29 weeks of gestational age.


Assuntos
Antibacterianos/administração & dosagem , Doenças do Prematuro/tratamento farmacológico , Infusões Intravenosas/instrumentação , Sepse/tratamento farmacológico , Vancomicina/administração & dosagem , Feminino , Humanos , Lactente , Recém-Nascido , Recém-Nascido Prematuro , Infusões Intravenosas/métodos , Masculino , Estudos Retrospectivos , Resultado do Tratamento
5.
Acta Gastroenterol Belg ; 74(4): 491-6, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22319957

RESUMO

BACKGROUND AND STUDY AIMS: Oxidative stress plays an important role in development of intestinal injury after abdomino-pelvic radiation therapy. Teucrium polium (TP) is a medicinal plant which has antioxidant and anti-inflammatory properties. The aim of this study was to investigate the effect of TP on radiation-induced intestinal oxidative damage in rats. MATERIALS AND METHODS: Group 1 (n = 8), the control group; Group 2 (n = 8), the RAD (radiation) group in which each rat received a single whole-body 800 cGy radiation performed with a LINAC ; Group 3 (n = 8), the RAD + TP group in which rats were exposed to radiation as in Group 2, followed by intragastric administration of 0.5 g/kg/daily TP extract for 7 consecutive days; and Group 4 (n = 8), the TP group, rats received only intragastric TP for 7 days. RESULTS: Radiation led to intestinal damage, which was accompanied by an increase in intestinal thiobarbituric-acid-reactive substances (TBARS) and myeloperoxidase (MPO) levels, and a decrease in reduced glutathione (GSH) levels. Although TP significantly decreased intestinal MPO levels and inflammation scores, it neither reverted intestinal TBARS and GSH levels nor ameliorated other histological parameters of the disease. CONCLUSIONS: Our results suggest that TP reduces inflammation but does not ameliorate the increased oxidative stress conditions in radiation-induced intestinal damage in rats.


Assuntos
Estresse Oxidativo , Fitoterapia , Teucrium , Animais , Intestinos/patologia , Intestinos/efeitos da radiação , Masculino , Ratos , Ratos Sprague-Dawley , Substâncias Reativas com Ácido Tiobarbitúrico
6.
Acta Gastroenterol Belg ; 72(4): 407-12, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-20163034

RESUMO

BACKGROUND AND STUDY AIMS: Abnormal expression of claudin-4 and beta-catenin play a role in carcinogenesis. The purpose of the present study was to examine claudin-4 and beta-catenin expression in normal and precancerous gastric mucosa. PATIENTS AND METHODS: Endoscopic biopsy specimens [normal gastric mucosa (n = 22), intestinal metaplasia (n = 24), dysplasia (n = 18), Helicobacter pylori (H. pylori)-associated chronic gastritis (n = 32) and remnant gastric mucosa (n = 18)] obtained from different 114 patients were examined by immunohistochemistry. RESULTS: Claudin-4 expression was present in 94.4% of dysplasia, 87.5% of intestinal metaplasia, 62.5% H. pylori-associated chronic gastritis, and 88.9% remnant gastric mucosa but only 18.2% of normal gastric mucosa biopsies. Decreased expression of beta-catenin was present in 27.8% of dysplasia, 8.3% of intestinal metaplasia, 15.6% of H. pylori-associated chronic gastritis, and 22.2% of remnant gastric mucosa biopsies, but was not present in normal gastric mucosa. When compared with normal gastric mucosa, there was a significant difference in claudin-4 expression in all groups (P < 0.05), but a significant difference was detected in dysplasia and remnant gastric mucosa for beta-catenin (P < 0.05). CONCLUSIONS: Our results suggest that claudin-4 expression is upregulated in premalignant gastric alterations.


Assuntos
Proteínas de Membrana/metabolismo , Lesões Pré-Cancerosas/metabolismo , Neoplasias Gástricas/metabolismo , beta Catenina/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Claudina-4 , Feminino , Mucosa Gástrica/metabolismo , Gastrite/metabolismo , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Regulação para Cima/fisiologia
7.
Acta Gastroenterol Belg ; 70(3): 293-5, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-18074740

RESUMO

Nitroimidazole derivatives are commonly used in the treatment of protozoal and anaerobic infections, and reports of their hepatotoxicity are rare. We report a case of severe hepatitis due to the long-term (8 weeks) use of ornidazole. A 27-year-old woman presented for evaluation of elevated serum transaminase and total bilirubin levels. Liver biopsy revealed portal inflammation, hepatocellular and canalicular cholestasis, porto-portal and portocentral bridging fibrosis, and a tendency to form nodules. No aetiological factors associated with chronic liver disease were identified. The abdominal ultrasonographic findings were compatible with chronic liver disease. We therefore made the diagnosis of severe hepatitis resulting from the long-term use of ornidazole. We conclude that nitroimidazole derivatives may lead to serious liver damage, especially in female patients.


Assuntos
Amebicidas/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Colestase Intra-Hepática/induzido quimicamente , Ornidazol/efeitos adversos , Adulto , Feminino , Seguimentos , Hepatomegalia/induzido quimicamente , Humanos , Icterícia/induzido quimicamente , Cirrose Hepática/induzido quimicamente
8.
Acta Gastroenterol Belg ; 69(3): 268-75, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17168122

RESUMO

BACKGROUND AND STUDY AIMS: Bacterial translocation (BT) has been implicated in the development of infectious complications in many serious clinical conditions such as fulminant hepatic failure (FHF). We aimed to investigate the effects of Gingko biloba (GB), vitamin E (Vit E) and melatonin on intestinal oxidative damage and BT in thioacetamide (TAA)-induced FHF in rats. MATERIALS AND METHODS: A total of 42 rats were divided into five groups. Group 1 (n = 8) was the control group. Group 2 (n = 10) was the TAA group, in which rats received 350 mg/kg TAA daily by the intraperitoneal (ip) route for 3 days. Oral 100 mg/kg GB per day was administered to group 3 (n = 8), oral 200 mg/kg Vit E per day to group 4 (n = 8) and ip 3 mg/kg melatonin per day to group 5 (n = 8) 48 h prior to the first TAA injection and was continued for 5 consecutive days. RESULTS: When compared with the control group, serious hepatic and intestinal oxidative damage, increased Escherichia coli counts in ileal aspirates and high BT frequencies were observed in the TAA group (all p < 0.0001). Only GB treatment attenuated hepatic oxidative damage (p < 0.0001). There was no difference in intestinal oxidative damage, E. coli counts in ileal aspirates and BT frequency between TAA and the other antioxidant treatment groups (p > 0.05). CONCLUSION: Our results suggest that intestinal oxidative damage plays a major role in the development of BT by disrupting the barrier function of intestinal mucosa.


Assuntos
Antioxidantes/uso terapêutico , Translocação Bacteriana/efeitos dos fármacos , Escherichia coli/fisiologia , Ginkgo biloba , Falência Hepática Aguda/induzido quimicamente , Falência Hepática Aguda/tratamento farmacológico , Melatonina/uso terapêutico , Tioacetamida/efeitos adversos , Vitamina E/uso terapêutico , Análise de Variância , Animais , Antioxidantes/farmacologia , Biomarcadores/sangue , Modelos Animais de Doenças , Mucosa Intestinal/metabolismo , Intestinos/efeitos dos fármacos , Intestinos/microbiologia , Intestinos/fisiopatologia , Peroxidação de Lipídeos/efeitos dos fármacos , Falência Hepática Aguda/metabolismo , Falência Hepática Aguda/microbiologia , Falência Hepática Aguda/mortalidade , Linfonodos/microbiologia , Masculino , Melatonina/farmacologia , Mesentério , Estresse Oxidativo/efeitos dos fármacos , Fitoterapia , Preparações de Plantas/farmacologia , Ratos , Baço/microbiologia , Taxa de Sobrevida , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Vitamina E/farmacologia
9.
Hum Exp Toxicol ; 25(12): 705-13, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17286148

RESUMO

Gingko biloba (GB) has antioxidant and platelet-activating factor (PAF) antagonistic effects. We investigated the protective effects of GB on thioacetamide (TAA)-induced fulminant hepatic failure in rats. Fulminant hepatic failure was induced in treatment groups by three intraperitoneal (ip) injections of TAA (350 mg/kg) at 24-hour intervals. Treatments with GB (100 mg/kg per day, orally) and N-acetylcysteine (20 mg/kg twice daily, sc) were initiated 48 hours prior to TAA administration. The liver was removed for histopathological examinations. Serum and liver thiobarbituric acid-reactive substance (TBARS) levels were measured for assessment of oxidative stress. Liver necrosis and inflammation scores and serum and liver TBARS levels were significantly higher in the TAA group compared to the control group (P < 0.001, < 0.001, 0.001, < 0.001, respectively). Liver necrosis and inflammation scores and liver TBARS levels were significantly lower in the GB group compared to the TAA group (P < 0.001, < 0.001 and 0.01, respectively). GB ameliorated hepatic damage in TAA-induced fulminant hepatic failure. This may be due to the free radical-scavenging effects of GB.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Sequestradores de Radicais Livres/farmacologia , Ginkgo biloba , Encefalopatia Hepática/prevenção & controle , Fígado/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacologia , Acetilcisteína/farmacologia , Alanina Transaminase/sangue , Amônia/sangue , Animais , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Modelos Animais de Doenças , Medicamentos de Ervas Chinesas/uso terapêutico , Sequestradores de Radicais Livres/uso terapêutico , Encefalopatia Hepática/sangue , Encefalopatia Hepática/induzido quimicamente , Encefalopatia Hepática/metabolismo , Encefalopatia Hepática/patologia , Fígado/metabolismo , Fígado/patologia , Masculino , Necrose , Estresse Oxidativo/efeitos dos fármacos , Inibidores da Agregação Plaquetária/uso terapêutico , Ratos , Ratos Wistar , Índice de Gravidade de Doença , Tioacetamida , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...